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MUC1, a transmembrane mucin, is a key modulator of several signaling pathways that affect oncogenesis, motility, and
cell morphology. The interaction of MUC1 cytoplasmic tail
(MUC1CT) with signal transducers and its nuclear translocation and subsequent biological responses are believed to be
regulated by phosphorylation status, but the precise mechanisms by which this occurs remain poorly defined. We
detected a novel association between the Met receptor tyrosine kinase and the MUC1CT. Met catalyzed phosphorylation
of tyrosine at YHPM in the MUC1CT. Stimulation of
S2-013.MUC1F pancreatic cancer cells with hepatocyte
growth factor facilitated nuclear localization of MUC1CT, as
determined by real time confocal imaging analysis. MUC1
overexpression also facilitated faster turnover of Met. Phosphorylation of MUC1CT by Met enhanced its interaction
with p53, which led to suppression of AP1 transcription factor activity through interactions at the MMP1 promoter, ultimately leading to reduced transcription of MMP1. This correlated with a decrease in hepatocyte growth factor-induced
invasiveness when MUC1 was overexpressed. The results
demonstrate that MUC1 modulates Met-mediated oncogenic
signaling in cancer.

Met, a receptor tyrosine kinase of the semaphorin family that
regulates cell growth, invasion, and cell survival, is a heterodimeric molecule consisting of a 50-kDa extracellular ␣ subunit and a 145-kDa transmembrane ␤ subunit (1). The cytoplasmic tail of Met contains a kinase domain and a C-terminal
docking site, which recruits adaptor proteins (2). These inter-
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actions are modulated by HGF,2 a ligand for Met that stimulates
phosphorylation at different residues of Met and on other substrates. Deregulated activation or overexpression of Met elicits
tumorigenic and metastatic effects and has been reported in
several cancers, including pancreatic adenocarcinoma (3–5).
HGF stimulation also induces degradation of Met and terminates Met signaling, thus bringing cells back to homeostasis.
Human MUC1, a type I transmembrane protein normally
expressed on the apical surface of ductal epithelia, is overexpressed and aberrantly glycosylated in several cancers, including pancreatic adenocarcinoma (6, 7). MUC1 is synthesized as a
single polypeptide chain but exists on the cell surface as a heterodimer. Co-translational proteolytic cleavage of the fulllength protein results in two associated fragments as follows: a
large extracellular polypeptide containing the tandem repeat
domain that can be released from the cell surface; and a
polypeptide consisting of the short extracellular region, the
transmembrane domain, and the cytoplasmic tail that exists as
an integral membrane protein (8, 9).
The cytoplasmic tail of MUC1 (MUC1CT) contains multiple
serine, threonine, and tyrosine residues, which are phosphorylated and involved in different signaling cascades in response to
changing cell surface conditions, including spatial reorganization or stimulation with growth factors and cytokines (8).
Changes in the phosphorylation status of MUC1CT are
believed to modulate its affinity for mediators of signal transduction, including ␤-catenin, p53, and Grb2-SOS.
The processes that regulate phosphorylation of the
MUC1CT and the specific kinases that catalyze these reactions
are now being elucidated. The MUC1CT is a substrate for
GSK3␤, c-Src, EGFR, and platelet-derived growth factor receptor-␤ (10 –13). Activated EGFR is reported to phosphorylate
the MUC1CT on tyrosine at a YEKV motif that functions as a
binding site for the c-Src Src homology 2 domain (12). EGFRmediated phosphorylation of MUC1CT induces binding of
MUC1CT to c-Src and enhances the binding affinity of
MUC1CT to ␤-catenin. Interactions of MUC1CT with ␤-catenin are diminished by GSK3-␤-mediated phosphorylation (12).
MUC1CT is translocated to the nucleus in association with
2

The abbreviations used are: HGF, hepatocyte growth factor; mAb, monoclonal antibody; MOPS, 4-morpholinepropanesulfonic acid; EYFP,
enhanced yellow fluorescent protein; MS/MS, tandem mass spectrometry;
ChIP, chromatin immunoprecipitation; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; EGFR, epidermal growth factor receptor.
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␤-catenin, where it may influence the activity of the latter as a
transcriptional co-activator (12, 16). Nuclear translocation of
MUC1CT is mediated by its interaction with importin ␤ and
nucleoporin Nup62 (17).
The in vivo phosphorylation status of MUC1CT and the
kinases that act on it in pancreatic cancer have not been well
characterized. We present evidence that the Met receptor tyrosine kinase interacts with MUC1 in pancreatic cancer cells, and
catalyzes phosphorylation of the MUC1CT in response to stimulation by HGF. Overexpression of MUC1 in pancreatic adenocarcinoma cells down-regulated conventional Met-mediated
signaling and inhibited motility and invasion. HGF stimulation
facilitated interaction of MUC1CT with p53, enabled p53-mediated suppression of AP1 transcriptional activity, and
decreased MMP1 expression. We conclude that Met-mediated
phosphorylation of MUC1 modulates signaling related to
motility and invasion in pancreatic cancer.

EXPERIMENTAL PROCEDURES
Cell Culture—Panc-1 was obtained from the American Type
Culture Collection (Manassas, VA). S2-013 is a cloned subline
of a human pancreatic tumor cell line (SUIT-2) derived from a
liver metastasis (18). HPAF2 pancreatic tumor cells have been
described previously (19, 20). FLAG epitope-tagged MUC1
(MUC1F) transfectants of the S2-013 cell line (S2013.MUC1F), Panc1 cell line (Panc1.MUC1F), and cytosolic
tail-deleted MUC1 transfectants of the S2-013 cell line (S2013.CT3), and Panc1 (Panc1.CT3) were cultured as described
previously (21). MDA-MB-435 cells, previously described as
breast cancer cells but recently reported to be of melanoma
origin (22, 23), were stably transduced with pLNCX.1 retroviral
vectors expressing wild type MUC1 or empty vector neo controls, as described previously (24), to produce MDA-MB435.MUC1 and MDA-MB-435.neo, respectively. HPAF2 cells
were maintained in Eagle’s minimal essential medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine
serum, nonessential amino acids, sodium pyruvate, and penicillin/streptomycin under similar conditions.
Immunoblotting and Immunoprecipitation—Cell lysate proteins were resolved on 10 or 14% NOVEX Tris-glycine denaturing polyacrylamide gels (Invitrogen) in a 1⫻ SDS-PAGE buffer
(1 g/liter SDS, 3 g/liter Tris base, and 14.4 g/liter glycine).
Immunoblotting and immunoprecipitations were performed as
described previously (14).
Biotinylation Assay—Cells serum-starved for 24 h were surface-biotinylated with EZ-link Sulfo-NHS-SS-Biotin (Pierce)
on ice followed by washing and quenching of free biotin, and
then incubated at 37 °C in the presence or absence of 100 ng/ml
HGF (100 ng/ml, PeproTech, Rocky Hill, NJ) for 2 h. Following
the 2-h incubation, cell monolayers were glutathione-stripped
as described by Graeve et al. (25). Cells were incubated in two
20-min washes of glutathione solution (60 mM glutathione,
0.083 M NaCl, with 0.083 M NaCl, and 1% bovine serum albumin
added before use) at 0 °C to remove the cell surface biotin
groups. The remaining biotinylated proteins, which were endocytosed prior to biotin stripping, were recovered from the RIPA
cell lysates by incubation with neutravidin beads (Pierce).
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In Vitro Kinase Assay—1 g of peptides in 10 l of reaction
buffer (Met reaction buffer: 40 mM MOPS, pH 7.5, 1 mM EGTA)
were incubated at 37 °C for 30 min along with 10 Ci of
[␥-32P]ATP and 500 ng of active human recombinant Met
(Upstate Cell Signaling Solutions, Lake Placid, NY). The reaction was stopped by boiling the samples in reducing SDS-sample buffer. Samples were resolved on 16% Tricine gel. The gel
was dried and analyzed by PhosphorImager analysis.
Metabolic Labeling of Cells and Radioimmunoprecipitation
Analysis—Metabolic labeling was performed as described previously (13). Briefly, HPAF2 cells were serum-starved for 24 h
and incubated in phosphate-free minimum essential medium
at 37 °C for 2 h prior to labeling with 2 mCi/ml [32P]orthophosphate (ICN, Irvine, CA) for 2 h in the presence or absence of
100 ng/ml HGF. Whole cell lysates were prepared with icecold radioimmunoprecipitation assay buffer. Radiolabeled
MUC1CT was immunoprecipitated by incubation with mAb
CT2 (mAb against MUC1CT) and resolved by SDS-PAGE on
a 14% gel.
Tandem MS Analysis of MUC1CT and Its Association
Partners—Immunoprecipitated MUC1CT from cell lysates or
in vitro phosphorylated MUC1CT peptides were resolved on
14% NOVEX Tris-glycine denaturing polyacrylamide gels
(Invitrogen), silver-stained, and then individual bands were
excised and trypsin-digested. Eluted peptides were analyzed
using a Q-TOF Ultima tandem mass spectrometer (Micromass/Waters) with electrospray ionization as described previously (13).
Cell Migration and Invasion Assays—In vitro invasive potential of cells with and without HGF stimulation were assayed
using the Biocoat migration or Matrigel invasion chambers (BD
Biosciences). S2-013.MUC1F, S2-013.CT3, and S2-013.Neo
cells (5 ⫻ 104) were seeded onto the upper chamber, which also
had a coating of Matrigel in the invasion chambers. The lower
chamber contained Dulbecco’s modified Eagle’s medium with
or without 100 ng/ml HGF. The chambers were cultured at
37 °C for 24 h in a CO2 incubator. Cells on the upper portion of
the membrane were wiped off with a cotton-tipped swab, and
cells on the bottom of this membrane were fixed and stained
with Diff-Quick staining kit (Allegiance) and observed by light
microscopy. The numbers of invading cells were counted in five
randomly selected observation fields per membrane at ⫻200
magnification.
Plasmids, Transient Transfections, and Luciferase Assays—
MMP-1 luciferase reporter, wild type or mutated at the first
ETS site 388/385 (GGAT to AAAT), AP-1-binding site (370 to
368 from GTC to TGG), or the second ETS site 348/345
(GGAA to AAAA) were a kind gift from Dr. Ralf Janknecht
(Mayo Clinic, Rochester, MN) (26). An AP1-responsive luciferase plasmid was obtained from Promega. PGL2 basic was used
as a control plasmid for transfection in luciferase studies. A dual
luciferase reporter assay (Promega) was used to detect promoter activity in this study. A synthetic Renilla luciferase
reporter plasmid pRL-SV40 (Promega) was used as a control for
transfection efficiency. 10,000 cells/well were seeded into a
48-well plate and grown to ⬃60% confluence and then serumstarved for 24 h and transfected using Lipofectamine 2000
VOLUME 283 • NUMBER 40 • OCTOBER 3, 2008
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reverse, TCGAAGGTAAGTGATGGCTTCC), or a control region 1.5
kb upstream of pMMP1 (forward,
TGCCTAGCACCAAGGAGCGAAGA; reverse, CGGAGTATGAGATAACTCCCC) as described in
the Superarray protocol.
Statististical Analysis—Results
are expressed as mean ⫾ S.E. of 3–5
independent experiments, each
treatment performed in triplicate.
Statistical analysis was performed
using the SPSS or GraphPad Prism
statistical software. Student’s t test
was used when appropriate. p ⬍
0.05 was considered significant.

RESULTS
MUC1CT Interacts with Met—
Proteomics techniques were used to
identify proteins that co-immunoprecipitated with MUC1 from
S2-013 pancreatic adenocarcinoma
cells, a moderately differentiated
human pancreatic tumor cell line
known to express O-glycosylated
mucin-like proteins, including low
levels of endogenous MUC1 (18). A
cDNA construct encoding a FLAG
epitope-tagged form of MUC1 (7)
FIGURE 1. Interaction of MUC1 with Met. A, identification of Met as an interaction partner for MUC1 by mass was overexpressed in the these cells
spectrometry. MUC1 was immunoprecipitated from S2-013.MUC1F and Panc1.MUC1F cells by mAb CT2 and
(S2-013.MUC1F). Immunoprecipiresolved on SDS-PAGE. The gel was silver-stained, and specific bands not observed in IgG control lanes were
excised and subjected to trypsin digestion followed by liquid chromatography-electrospray ionization-mass tations with the CT2 antibody,
spectrometric analysis. This analysis identified a tryptic fragment of Met indicated in the illustration. B, inter- which binds to MUC1CT, were
action of MUC1 and Met was confirmed by reciprocal co-immunoprecipitation. MUC1 was immunoprecipitated (IP) from Panc1.MUC1F, S2-013.MUC1F, and HPAF2 pancreatic adenocarcinoma cells and immuno- resolved on Tris-glycine SDS-PAGE
blotted (IB) for Met by using a polyclonal Ab for the cytoplasmic tail of Met. A reciprocal immunoprecipitation and silver-stained (supplemental
of Met and immunoblotting with HMFG2 mAb raised against the tandem repeat region of MUC1 was also Fig. 1). Bands representing specific
performed (right panel).
proteins that co-immunoprecipitated with MUC1 and were absent
(Invitrogen), with and without 100 ng/ml HGF, and cultured for from isotype control lanes were excised from the gel and subanother 24 h. The cells were then washed twice with phosphate- jected to in-gel trypsin digestion and MS/MS analysis for probuffered saline and harvested with 200 l of Passive Lysis buffer tein identification. A fragment corresponding to the cytoplas(Promega) and assayed for the luciferase activities. Each exper- mic tail of Met, FTVKVADFGLAR, was identified by this
approach (Fig. 1A).
iment was performed three times in triplicate.
We performed reciprocal co-immunoprecipitations of
Chromatin Immunoprecipitation (ChIP) Assays—5.0 ⫻ 107
S2-013MUC1F cells were prepared for ChIP assays by cross- MUC1 and Met from cell lysates of three human pancreatic
linking for 30 min with 50 mM (10-fold molar excess) dimethyl adenocarcinoma cell lines as follows: Panc1.MUC1F (a poorly
3,3⬘-dithiobispropionimidate䡠2 HCl (Pierce), followed by 10 differentiated cell line overexpressing a FLAG-tagged MUC1
min of cross-linking with 1% formaldehyde. The cross-linkers construct); S2-013.MUC1F; and HPAF2 (a highly differentiated
were quenched with 125 mM glycine in phosphate-buffered cell line with high endogenous levels of MUC1). Immunopresaline. The cells were scraped and sonicated to an average of cipitations utilizing anti-cytoplasmic tail antibodies for both
500 bp to prepare the chromatin as per the Affymetrix ChIP molecules (Fig. 1B) were resolved on 10% SDS-PAGE to faciliprotocol, which was subjected to immunoprecipitation with tate separation of pre-Met (unprocessed form) and Met and
either CT2 or IgG control. The immunoprecipitants were Western blotted, and the membranes were probed with
washed and eluted as suggested by the protocol, and 3.0 l of HMFG-2 (a monoclonal antibody against the tandem repeat
the eluted product was subjected to real time PCR using primer region of MUC1) or an antibody against the Met cytoplasmic
sets for pGUSB (Superarray Bioscience Corp., Frederick, tail. The immunoblotting results revealed consistent interacMD), pMMP1 (forward, TGGCAGAGTGTGTCTCCTTCGC; tions between MUC1 and Met in S2-013.MUC1F and HPAF2
OCTOBER 3, 2008 • VOLUME 283 • NUMBER 40

JOURNAL OF BIOLOGICAL CHEMISTRY

26987

Phosphorylation of MUC1 by Met
proteins that were endocytosed.
Ammonium chloride was used to
block lysosomal degradation of
endocytosed proteins. Proteins
from whole cell lysates were immunoprecipitated by using Neutravidin beads and subsequently immunoblotted for Met. HGF stimulation
caused a significant reduction in
total levels of Met protein in a temporal manner in S2-013.MUC1F
cells (Fig. 2A). However, steady
state levels of Met were comparatively stable in S2-013.Neo
cells (which do not overexpress
MUC1), suggesting that MUC1
overexpression facilitated faster
turnover of Met during stimulation with HGF. The increased
turnover of Met in S2-013.MUC1F
cells following HGF stimulation
was also associated with reduced
binding to Gab1, as demonstrated
by immunoprecipitation followed
by immunoblotting (Fig. 2B).
FIGURE 2. MUC1 promotes endocytosis, lysosomal degradation, and reduced signaling of Met. A, effect of However, the interactions of
MUC1 overexpression on Met endocytosis was determined in S2-013.MUC1F or S2-013.neo cells. Serum- Met with Gab1 were higher in
starved cells were surface-biotinylated on ice and then incubated at 37 °C for 2 h in the absence (serum-free or
SF) or presence of HGF (H) to allow endocytosis. Surface-biotinylated proteins from RIPA lysates were recovered S2-013.MUC1F cells under serumon neutravidin beads and analyzed by SDS-PAGE, followed by Western blotting with a polyclonal Ab against starved steady state conditions, as
Met. 1st 3 lanes indicate the total levels of surface-biotinylated Met after 2 h of incubation at 0, 37, or 37 °C in the
compared with the S2-013.Neo
presence of HGF and ammonium chloride, and 4th to 6th lanes represent the levels of endocytosed Met
(detected by glutathione stripping or GS) under serum-free conditions or HGF stimulation with and without cells.
ammonium chloride. B, effect of HGF stimulation on Met signaling. S2-013.MUC1F or S2-013.neo cells were
In Vitro Phosphorylation of
stimulated with HGF for different times. Lysates were immunoprecipitated with Met cytoplasmic tail Ab or IgG
MUC1CT
by Met—We investigated
control. The immunoprecipitants were resolved on SDS-PAGE and immunoblotted (IB) with Abs against Gab1
or Met.
whether Met phosphorylated the
MUC1CT by performing in vitro
cells, and a weaker interaction was observed for Panc-1.MUC1F kinase assays with a 66-mer MUC1CT peptide (MUC1CT-p66,
cells. Although the reason for the weaker interaction between representing the C-terminal 66 residues of 72-residue-long
MUC1 and Met in Panc1.MUC1F cells is not definitively MUC1CT) and recombinant active human Met kinase, in the
known at this time, it is known that Panc1 is a poorly differen- presence of [␥-32P]ATP. Autoradiograms from 32P-labeled in
tiated pancreatic cancer cell line (27) that attaches core 1 type vitro kinase reactions showed phosphorylation of MUC1CTshort oligosaccharides (e.g. sialyl-Tn and sialyl-T) to MUC1 p66 in the presence of Met (Fig. 3A, 3rd lane). No phosphorylbecause of a lack of expression of core 2 GlcNAc transferase ation was observed in the absence of peptide (Fig. 3A, 2nd lane),
activity (28). In contrast, S2-013 and HPAF2 are moderately or kinase (1st lane). Parallel reactions were applied to SDSand well differentiated pancreatic cancer cell lines, respectively, PAGE followed by silver staining (Fig. 3A, bottom panel). Bands
that attach to MUC1 extended oligosaccharides such as sialyl corresponding to the MUC1CT peptide were digested with
Lewis A (7) and sialyl Lewis C. This raises the possibility that trypsin and sequenced by tandem mass spectrometry. The
glycosylation of MUC1 influences its ability to interact with mass spectrometric analysis of MUC1CT revealed phosphoMet. Both pre-Met and Met were found to interact with MUC1. rylation at tyrosine at the YHPM motif (or Tyr-1203, NCBI
MUC1 Facilitates Faster Turnover of Met—Because MUC1 accession number P15941; Fig. 3B). Furthermore, MUC1CT
and Met were in complex, we sought to determine whether peptide synthetically pre-phosphorylated at tyrosine in the
overexpression of MUC1 modulates stability of Met by YHPM motif (MUC1CT-p66-pYHPM) was not phosphorylperforming cell surface biotinylation experiments (25). ated by Met (Fig. 3A).
S2-013.MUC1F and S2-013.Neo cells were serum-starved for
Increased MUC1CT Phosphorylation by HGF Stimulation of
24 h and then surface-biotinylated with a cell-impermeable Pancreatic Adenocarcinoma Cells—To investigate the in vivo
biotinylation reagent. The surface-biotinylated cells were stim- phosphorylation of MUC1CT by Met in pancreatic adenoulated with HGF (100 ng/ml) for 0, 15, 60, or 120 min. The cells carcinoma cells, HPAF2 cells were serum-starved for 24 h
were glutathione-stripped to remove biotin from the nonendo- followed by 2 h of incubation with 100 ng/ml recombinant
cytosed cell surface proteins, thus specifically biotin-labeling human HGF, an activating ligand for Met, in the presence of
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FIGURE 3. Met mediates phosphorylation and nuclear localization of MUC1CT. A, recombinant active Met kinase phosphorylated MUC1CT-p66. MUC1CTp66 or MUC1CTp66-pYHPM peptides were incubated with Met kinase in the presence of [␥-32P]ATP. The reaction mixtures were resolved on SDS-PAGE
followed by autoradiography or the gel was stained with Coomassie Blue. B, MS/MS spectra of trypsinized phospho-MUC1CT-p66 from in vitro kinase reactions.
MS/MS spectra of DTYHPMSEYPTYHTHGR peptide from Met-phosphorylated MUC1CT-p66 indicates phosphorylation of Y1. 32P labeling of HPAF2 cells was
performed under HGF stimulation (C). HPAF2 cells were labeled with [32P]orthophosphate (250 Ci/ml) in the presence (3rd lane) or absence (1st lane) of human
recombinant HGF (100 ng/ml), lysed in RIPA buffer, immunoprecipitated (IP) with mAb CT2, and subjected to autoradiography or immunoblotting with mAb
CT2. Immunoprecipitation with a nonspecific mAb was used as an IP control (2nd lane). Nuclear (N) and cytoplasmic (C) localization of MUC1CT from
S2-013.MUC1F cells (D) and HPAF2 cells (E) phosphorylated at tyrosine at the YHPM site were determined by Western blotting with phosphorylation sitespecific antibody. The polyvinylidene difluoride membrane was reprobed with antibodies against H2B and ␤-actin as controls for protein loading. F, left panel,
S2-013.MUC1.CT-EYFP cells expressing MUC1 with C-terminally tagged EYFP were utilized for real time laser scanning confocal microscopy. The first two scans
were taken under serum-starved conditions, and HGF (100 ng/ml) was added to the culture disk right after the second scan, and successive scans were taken
for 15 min, every 10 s at 37 °C at ⫻100 magnification. After the first 15 min, the rest of the scans were performed every 2.5 min for a total period of 4 h.
Representative real time confocal scans of a cluster of cells and a single cell are presented here. G, S2-013.MUC1F or S2-013.MUC1FHPM cells were serumstarved for 24 h, stimulated with HGF for 15 min, or left unstimulated, fixed, and permeabilized before incubation with mAb CT2 and the nuclear dye propidium
iodide. The mAb CT2 (anti-MUC1CT) was visualized as blue (right panel) and detected by using a Cy5-conjugated secondary antibody, and nuclei were
visualized in red. White arrows indicate localization of MUC1CT outside the nucleus.

[32P]orthophosphate. MUC1 was immunoprecipitated from
cell lysates with CT2 mAb and separated by SDS-PAGE, and
proteins were transferred onto a polyvinylidene difluoride
membrane, which was then subjected to autoradiography.
Cell lysates from unstimulated cells and lysates immunoprecipitated with an isotype identical Ab were used as controls.
OCTOBER 3, 2008 • VOLUME 283 • NUMBER 40

A duplicate gel was immunoblotted with CT2 antibody to
identify the MUC1CT bands. Autoradiography revealed that
in vivo labeling of HPAF2 cells with [32P]orthophosphate
following stimulation with HGF induced a significant
increase in phosphorylation of MUC1CT, as compared with
unstimulated cells (Fig. 3C).
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 4. MUC1 abrogates HGF-stimulated motility and invasion. S2-013.Neo, S2-013.MUC1F, or S2-013.MUC1.FHPM cells were added to the upper
compartment of migration or invasion chamber in serum-free culture media. HGF-containing media were added to the lower chamber. After 24 h of incubation, cells in the upper chamber were removed, and cells that had migrated or invaded onto the lower surface of the membrane were stained and counted in
10 different fields of light microscopy. Bars represent mean ⫾ S.E. of migrating (A) or invading cell number (B) from three independent experiments performed
in triplicate (*** indicates p ⬍ 0.001 and ** indicates p ⬍ 0.01). To study the actin cytoskeleton changes, cells were serum-starved for 24 h or stimulated with HGF
for 2 h post-serum starvation. The actin cytoskeleton was visualized with Alexa-488-conjugated phalloidin (green), and the nuclei were stained with propidium
iodide (red) and analyzed by laser scanning confocal microscopy (A). The horizontal size bars represent 20 m.

HGF Stimulation Causes Nuclear Localization of MUC1CT
Phosphorylated at Tyrosine in the YHPM Motif—A rabbit polyclonal antibody specific for phosphorylated tyrosine at the
YHPM site in MUC1CT (anti-pYHPM) was developed and utilized to evaluate the effect of HGF stimulation on MUC1CT
phosphorylation. The antibody has been described previously
(13). Nuclear and cytoplasmic extracts from HGF-stimulated
S2-013.MUC1F and HPAF2 cells were resolved on SDS-PAGE
followed by Western blotting with the anti-pYHPM antibody.
The results revealed a significant increase in phosphorylation of
tyrosine in the YHPM motif that was concordant with an
increased duration of HGF stimulation, mostly observed in the
nuclear fraction (Fig. 3, D and E).
Real time laser scanning confocal imaging was performed on
S2-013 cells stably transfected with C-terminally tagged EYFP
(S2-013.MUC1.CT-EYFP). The cells were serum-starved for
24 h and then stimulated with HGF (100 ng/ml) after two initial
scans to establish steady state localization under unstimulated
conditions. HGF stimulation significantly enhanced the
nuclear localization of MUC1CT from cytoplasmic and cell
surface locations within seconds to minutes of stimulation (Fig.

26990 JOURNAL OF BIOLOGICAL CHEMISTRY

3F). By 15 min post-stimulation, there was significant turnover
of MUC1CT.
The effects of HGF stimulation on nuclear localization of
MUC1CT were also evaluated by immunofluorescence analysis
with the CT2 mAb (raised against the MUC1CT) after
paraformaldehyde fixation of the serum-starved or HGF-stimulated S2-013.MUC1 cells. HGF stimulation significantly
enhanced the nuclear localization of MUC1CT (Fig. 3G). Furthermore, mutating a tyrosine in the YHPM motif to phenylalanine (S2-013.MUC1.FHPM) significantly abrogated the effect
of HGF stimulation on nuclear localization of MUC1CT.
Responses to HGF Stimulation of Met Are Down-regulated by
MUC1—We evaluated the effect of MUC1 overexpression on
HGF stimulation of migration by in vitro motility and invasion
assays performed in Boyden chambers with S2-013.MUC1F
and S2-013.Neo. MUC1 expression has been shown to facilitate
steady state in vitro motility and invasion in pancreatic adenocarcinoma cells (27, 28), and this was confirmed by the data
presented in Fig. 4 (S2013.Neo cell migration is less than
S2013.MUC1 under unstimulated conditions). Similar results
were observed with the MUC1-transfected and control cancer
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FIGURE 5. MUC1 abrogates HGF-stimulated activation of MMP1 expression. S2-013.MUC1F and S2-013.Neo cells were cultured to 60% confluence,
serum-starved for 24 h, and then stimulated with platelet-derived growth factor (PDGF) (50 ng/ml) or HGF (100 ng/ml) for 24 h or left unstimulated.
A, expression of MMP1 was determined by semiquantitative reverse transcription-PCR. The expression of ␤-actin was determined as a control. MMP1
promoter-luciferase reporter activity was assayed in S2-013.MUC1F, S2-013.CT3, and S2-013.Neo cells (B) as well as Panc1.MUC1F, Panc1.CT3, and
Panc1.Neo cells (C) under HGF stimulation. Cells were cotransfected with ⫺512hMMP1 luciferase reporter plasmid and Renilla luciferase plasmid
(control for transfection efficiency). Cells were subsequently stimulated with HGF (100 ng/ml) or left unstimulated for 24 h. Cells were harvested, and
proteins were assayed for dual luciferase activity. Three independent transfections were performed in triplicate, and the results are expressed as the
mean of relative light units normalized with Renilla luciferase activity ⫾ S.E. (*** indicates p ⬍ 0.001).

cell lines MDA-MB-435.Neo and MDA-MB-435.MUC1 (data
not shown). There was an ⬃16-fold increase in the number of
S2-013.Neo cells migrating to the other side of the filter in
response to HGF-containing medium, as compared with nonstimulated controls. The magnitude of this increase in response
to HGF stimulation was reduced by half (to 8-fold) for
S2-013.MUC1F cells (Fig. 4A). The differences in HGF-stimulated motility of S2-013.MUC1F and S2-013.Neo cells were statistically significant (p ⬍ 0.0001). Similar results (although
smaller in scale) were obtained when MDA-MB-435 cells were
evaluated in the same manner. Stimulation of MDA-MB435.Neo cells with HGF produced a 70% increase in motility,
but there was only a 35% increase in motility in MDA-MB435.MUC1 cells expressing MUC1 (data not shown, 4 independent experiments with 3 replicates each). Evidence of differences in motility between S2-013.MUC1F and S2-013.Neo
cells was also reflected in the lamellipodial structures observed
by Alexa488-Phalloidin staining, with and without HGF stimulation (Fig. 4A). S2-013.Neo cells showed significantly more
lamellipodial structures during HGF stimulation, as compared
OCTOBER 3, 2008 • VOLUME 283 • NUMBER 40

with S2-013.MUC1F cells. Similarly, results of Matrigel invasion assays under HGF stimulation (Fig. 4B) revealed that
S2-013.Neo cells exhibited greater than 8-fold increases in in
vitro invasiveness as compared with S2-013.MUC1F cells,
which showed modest increases of ⬃2.5-fold (p ⬍ 0.0001). The
cancer cell line MDA-MB-435.neo showed a 4.5-fold increase
in invasiveness upon stimulation with HGF, which was
decreased slightly to a 4.0-fold increase in MDA-MB435.MUC1 cells expressing MUC1 (data not shown, 4 independent experiments with 3 replicates each). S2-013.
MUC1.FHPM cells did not show significant abrogation of
HGF-induced invasiveness (Fig. 4B).
MUC1 Abrogates HGF-stimulated Transcriptional Activation of MMP1—HGF stimulation of Met has been implicated in transcriptional activation of MMP1, leading to
enhanced invasiveness in different cancer cell types (29, 30).
We evaluated S2-013.MUC1F and S2-013.Neo cells for
MMP1 mRNA expression by semiquantitative reverse transcription-PCR. MUC1 overexpressing cells showed no
increase in MMP1 mRNA expression under HGF stimulaJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 6. AP1 transcriptional activity is down-regulated by MUC1 and is crucial for HGF-mediated activation of MMP1 promoter activity. S2-013
(A) and Panc1 cells (B) were cotransfected with ⫺512hMMP1 luciferase reporter plasmid or the mutant reporter plasmids and Renilla luciferase plasmid.
The ⫺512hMMP1 luciferase reporter plasmids were either wild type (WT) or contained mutations in the first ETS region (ETS1), the AP1-binding region
(AP1), or the second ETS region (ETS2). Cells were subsequently stimulated with HGF (100 ng/ml) or left unstimulated for 24 h. Cells were harvested, and
proteins were assayed for dual luciferase activity. S2-013.MUC1F and S2-013.Neo cells were co-transfected with pAP1-luciferase reporter plasmid and
Renilla luciferase plasmid (C). Cells were subsequently stimulated with HGF (100 ng/ml) or left unstimulated for 24 h and analyzed for AP1-responsive
promoter activity. Three independent transfections were performed in triplicate, and the results are expressed as the mean of relative light units
normalized with Renilla luciferase activity ⫾ S.E. (*** indicates p ⬍ 0.001, ** indicates p ⬍ 0.01, and * indicates p ⬍ 0.05).

tion (Fig. 5A); however, MMP1 expression was enhanced in
response to HGF in S2-013.Neo cells. As a control, stimulation with platelet-derived growth factor resulted in
increased MMP1 expression in both cell types. To confirm
these findings, we evaluated the activity of an MMP1 promoter luciferase reporter plasmid system. The results of
these assays indicated significantly higher HGF-stimulated
activation of the reporter system in S2-013.Neo and
Panc1.Neo cells as compared with S2-013.MUC1F (Fig. 5B)
and Panc1.MUC1F cells (Fig. 5C), respectively. However,
expression of a truncated cytoplasmic tail construct of
MUC1 (S2-013.CT3 and Panc1.CT3) did not abrogate the
HGF-mediated increase in MMP1 expression. These results
indicated that MUC1CT down-regulated HGF-mediated
activation of MMP1 promoter activity.
MUC1 Abrogates HGF Stimulation-mediated Activation of
AP1 Transcription Factor Activity—We investigated the role
of different DNA elements in the regulation of MMP1
expression upon HGF stimulation by utilizing MMP1 promoter-luciferase reporter constructs having mutations in
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the first ETS region (ETS1), the AP1-binding region, and the
second ETS region (ETS2) (24). Assays with these promoterluciferase reporter constructs showed that mutating the ETS
regions significantly decreased luciferase reporter activity;
however, the mutated ETS luciferase reporters still showed a
2-fold increase in reporter activity upon stimulation with
HGF (Fig. 6, A and B). Constructs with mutations in the
AP1-binding region showed greatest decrease in the reporter
activity, and the effect of HGF stimulation was also totally
abrogated. This supports the hypothesis that the AP1 transcription factor is involved in the HGF-stimulated regulation
of MMP1 promoter activity. Because MUC1 also abrogated
the effect of HGF stimulation, we evaluated the effect of
MUC1 on AP1-dependent transcriptional activity under
HGF stimulation by evaluating transcriptional activity with
an AP1-responsive promoter-luciferase reporter construct.
The S2-013.Neo cells showed a 4-fold increase in AP1-responsive luciferase reporter activity under HGF stimulation,
as compared with serum-starved conditions (Fig. 6C). However, the S2-013.MUC1F cells showed no significant increase
VOLUME 283 • NUMBER 40 • OCTOBER 3, 2008
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FIGURE 7. Phosphorylation of MUC1CT by Met enhances interaction with p53 and activation of p53 further down-regulates MMP1 expression in the
presence of MUC1. Serum-starved or HGF-stimulated S2-013.MUC1F cell extracts were co-immunoprecipitated (IP) with CT2 mAb or isotype control antibody
and immunoblotted (IB) for p53 (A). S2-013.MUC1F, S2-013.MUC1.FHPM, and S2-013.MUC1.EHPM cells were also analyzed for the effect of phosphorylation
abrogating or mimicking mutations at tyrosine in the YHPM motif for their effect on interaction of MUC1 with p53 by co-immunoprecipitations (B). Serumstarved or HGF-stimulated S2-013.MUC1F and S2-013.Neo cells were co-transfected with MMP1 promoter luciferase reporter constructs, and the promoter
activity was assayed in the presence or absence of etoposide treatment (10 M), to activate p53 (C) (* indicates p ⬍ 0.05). Promoter occupancy of MUC1CT at
MMP1 promoter (pMMP1) under serum-starved and HGF-stimulated conditions was determined by performing ChIP assay on S2-013.MUC1 cells by utilizing
CT2 mAb or control IgG followed by real time PCR with pMMP1 primers, primers to the 1.5-kb region upstream of pMMP1 or GUSB primers. The amount of
pMMP1 immunoprecipitated with CT2 was normalized with input and plotted as relative amounts of pMMP1 immunoprecipitated with CT2 compared with the
serum-starved conditions ⫾ S.E. (D). The PCR products were also visualized on a gel to determine the specificity of amplification after 40 cycles (E). The
experiment was performed in triplicate.

in AP1-responsive luciferase reporter activity under HGF
stimulation.
HGF Stimulation Facilitates Interaction of MUC1CT with
p53 and Activates p53 to Abrogate MMP1 Expression—Previous studies have reported interactions between MUC1 and p53
in the region of MUC1CT containing the Met phosphorylation
site (33). Because it has also been reported that p53 can block
the interaction of AP1 transcription factor with basal transcription machinery to abrogate MMP1 expression, we wanted to
determine whether Met-phosphorylated MUC1 contributed to
effects of p53 on MMP1 promoter activity (34 –36). We investigated this possibility by performing co-immunoprecipitation
of MUC1 and p53 from serum-starved and HGF-stimulated
S2-013.MUC1F cells. Immunoprecipitations with the CT2
antibody against the MUC1CT were resolved on SDS-PAGE
and subjected to immunoblotting with an anti-p53 pAb. HGF
stimulation of S2-013.MUC1F cells significantly enhanced the
interaction of MUC1CT with p53 (Fig. 7A). Furthermore,
mutating a tyrosine in the YHPM motif to phenylalanine significantly abrogated this association, while mutating the same residue to glutamate (providing a phosphorylation-mimicking
negative charge) significantly enhanced the interaction of
MUC1 with p53 (Fig. 7B).
Having established the effect of HGF stimulation on interaction of MUC1CT with p53, we wanted to determine whether
activation of p53 affected the MUC1-mediated abrogation of
MMP1 promoter activation. For this purpose, we stimulated
S2-013.MUC1F and S2-013.Neo cells with HGF in the presence
or absence of 50 M etoposide, an activator of p53 (37, 38).
Etoposide treatment significantly decreased MMP1 expression
in the presence or absence of HGF stimulation of
S2-013.MUC1F cells (Fig. 7C). However, etoposide treatment
OCTOBER 3, 2008 • VOLUME 283 • NUMBER 40

enhanced MMP1 promoter activity in S2-013.Neo cells, suggesting that MUC1 overexpression augmented the inhibitory
activity of p53 on the MMP1 promoter in pancreatic adenocarcinoma cells.
MUC1CT Physically Occupies the MMP1 Promoter and Promoter Occupancy Is Enhanced by HGF Stimulation—Given the
evidence presented here that the MUC1CT was acting as a transcriptional co-regulator, and has been shown to physically
occupy different promoter elements (33), we sought to determine whether MUC1CT was present in transcriptional complexes at the MMP1 promoter, and if promoter occupancy was
regulated by HGF stimulation. A quantitative ChIP assay demonstrated greater than 3-fold increases in MMP1 promoter
(pMMP1) occupancy by MUC1CT at the AP1-binding site following HGF stimulation as compared with serum-starved conditions at 24 h (Fig. 7, D and E). Control IgG ChIP assays
showed no enrichment at the pMMP1 site. As an additional
control, we tested for enrichment of other unrelated elements
(GUSB promoter) when immunoprecipitated with CT2 from
serum-starved and HGF-stimulated cells, and MMP1 promoter
occupancy was normalized to GUSB promoter occupancy.
Also, no enrichment was detected at sites 1.5 kb upstream of the
MUC1-binding region in the MMP1 promoter.

DISCUSSION
In this study, we identified Met as a novel interaction partner
and kinase for the MUC1CT. We demonstrated that MUC1
associates with Met in pancreatic tumor cells, and under conditions of HGF stimulation MUC1 promotes endocytosis and
increased turnover of Met. Overexpression of MUC1 downregulated HGF stimulation-induced interaction of Met with
conventional downstream signal transducers and inhibited
JOURNAL OF BIOLOGICAL CHEMISTRY
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subsequent biological responses (motility and invasion). The
results clearly demonstrate that MUC1 is a regulator of Met
signaling in pancreatic adenocarcinoma cells.
Our results demonstrate that under serum-starved conditions, which might simulate the effects of autocrine growth factor stimulation, MUC1-overexpressing cells have higher Met
signaling activity, as indicated by greater steady state interaction with Gab1. These findings suggest that MUC1 facilitates
activation of Met in an environment that contains low levels of
HGF. Hence, MUC1 expression may confer on tumors a greater
propensity to metastasize when present in low HGF tissue environments. Conversely, MUC1 also down-regulated HGF-stimulated activation of motility and invasion under conditions of
high HGF concentrations. Additional indirect evidence of this
biological effect was provided by our observation of down-regulation of HGF-mediated transcriptional activation of MMP1
in MUC1-overexpressing cells, which is discussed further
below. MMP1 is a well known target of Met activation and is a
regulator of metastasis by virtue of its extracellular matrix
degrading activity (32).
Previously, the C terminus of another transmembrane mucin
expressed in the kidney, MUC20, was shown to associate with
Met and impair downstream signaling through the Grb2-RasERK1/2 pathway by blocking Grb2 recruitment to HGF-activated Met (39), without affecting signaling through Gab1/
phosphatidylinositol 3-kinase pathways. That these effects
were distinct from the pathways affected by interactions
between MUC1 and Met suggests that interactions between
cell surface mucins and Met are important and specific modulators of Met signaling activity. The tissue-specific patterns
of expression of different transmembrane mucins may thus
confer tissue-specific effects on Met signaling, both constitutive and HGF-stimulated.
High expression of HGF and Met has been reported in both
early and late neoplastic ductal lesions of pancreatic cancer,
suggesting that this may comprise an autocrine regulatory circuit (40). However, fully neoplastic and invasive cells lack the
expression of Met, which has been further correlated with poor
survival of cancer patients (40). It has been proposed for pancreatic cancer that up-regulation of Met receptor expression
and HGF-Met interaction may have a crucial role in early stages
of neoplasia, although subsequent loss may promote more
aggressive behavior of tumor cells (40). MUC1-facilitated turnover of Met might reflect a similar biological phenomenon.
Also, it is expected that activation of Met, which is well known
to induce cell scattering, might be crucial during early phases of
metastatic spread of cancer cells and also contribute to early
stages of survival at different metastatic sites. However, once
cells are established at different locations, they may turn off Met
to facilitate growth of a compact tumor mass. MUC1-mediated
endocytosis (which we demonstrate in this report) might
down-regulate levels of Met at the cell surface under conditions
of high HGF concentrations.
We demonstrated that Met is a kinase for MUC1CT, phosphorylating the latter at a tyrosine in the YHPM motif. What is
the biological role of Met-mediated phosphorylation of
MUC1CT? Previous studies have indicated that tyrosine phosphorylation of MUC1CT is crucial for its nuclear localization
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(8, 13). Real time confocal imaging of MUC1-GFP constructs as
well as confocal imaging of fixed cells post-HGF stimulation
were consistent with the hypothesis that there are pools of cell
surface and intracellular (perhaps pre-endocytic or endocytic)
MUC1CT under steady state conditions, and that stimulation
with HGF induced nuclear localization of MUC1CT from these
compartments within seconds to minutes of stimulation. Western blotting analysis of nuclear and cytoplasmic extracts of
S2-013.MUC1F cells indicated that a majority of the YHPM
phosphorylated fraction of MUC1CT is rapidly transported to
and resident in the nucleus. It should be noted that although the
in vitro studies prove that there is a direct kinase-substrate relationship between Met and MUC1, the phosphorylation of
MUC1 detected upon HGF stimulation in cells could also be
indirect and mediated through other kinases that are activated
downstream of Met.
In this study, we also investigated the functional role of
nuclear localization of MUC1CT post-HGF stimulation. We
showed that HGF stimulation facilitated interaction of
MUC1CT with p53, and phosphorylation of MUC1CT at tyrosine in the YHPM motif significantly enhanced its interaction
with p53. The p53 protein has been reported previously to
down-regulate MMP1 promoter activity by abrogating the
interaction of AP1 transcription factor with basal transcriptional machinery (34 –36). Our studies show that MUC1 blocks
the HGF-mediated activation of AP1 transcriptional activity.
Moreover, overexpression of MUC1 abrogates MMP1 promoter activity in a manner that is regulated by the AP1 transcription factor, which is further suppressed by etoposide-mediated activation of p53. However, control cells lacking MUC1
expression do not show p53-mediated inhibitory effects on
MMP1 promoter activity, suggesting that interaction of p53
with MUC1CT facilitates the inhibitory effect of p53 on the
MMP1 promoter.
The results presented here provide the first evidence that
MUC1CT physically occupies the MMP1 promoter. The
presence of MUC1CT in the transcriptional complex at the
MMP1 promoter, which is further facilitated by HGF stimulation and occurs in the region of the promoter bound by
p53 and AP1, significantly inhibited MMP1 promoter activity. Hence these studies suggest a transcriptional co-repressor role for MUC1CT.
Overall, this study provides insight into a mechanism by
which MUC1, a cell surface associated mucin, engages in morphogenetic signal transduction, by directly influencing the
steady state levels of protein expression of an associated receptor tyrosine kinase (Met), its downstream signaling, and by
enacting a unique signal transduction pathway in which phosphorylated MUC1CT associates with p53 and modulates transcription of the MMP1 gene. Our findings demonstrate that
signaling in response to HGF stimulation is influenced at multiple levels by interactions between Met and MUC1, including
influences on conventional Met signaling, and the induction of
a specific signaling pathway that involves the phosphorylated
MUC1CT. Given that MUC1 and Met are overexpressed in
pancreatic adenocarcinoma, further studies of MUC1 and Met
signaling should provide additional insights into the molecular
VOLUME 283 • NUMBER 40 • OCTOBER 3, 2008
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mechanisms that regulate invasion and metastasis of pancreatic
cancer.
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Supplemental Figure 1: Silver stained gel image. MUC1CT was immunoprecipitated from S2-013.MUC1F cells by utilizing control IgG
or CT2 mAb. The immunoprecipitants were resolved on tris glycine SDS-PAGE and silver stained. The indicated band was
identified as Met receptor tyrosine kinase.

